HUMALOG MIX 50/50 PEN (insulin lispro) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 1999.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
HUMALOG MIX 50/50 PEN is a rapid-acting insulin lispro analog administered by injection for Type 1 and Type 2 diabetes mellitus, chronic kidney disease, and acute myocardial infarction. It works by stimulating peripheral glucose uptake in muscle and fat while inhibiting hepatic glucose production, lipolysis, and proteolysis. The 50/50 formulation combines rapid-acting and intermediate-acting insulin for flexible dosing throughout the day.
Facing moderate competitive pressure (30/100) in a market dominated by GLP-1 agonists and SGLT2 inhibitors; brand teams should anticipate contraction and focus on retention and lifecycle extension strategies.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
Worked on HUMALOG MIX 50/50 PEN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on HUMALOG MIX 50/50 in a LOE-approaching environment means joining a consolidating franchise with limited growth opportunity but potential for defensive strategy expertise and market access acumen. Career progression depends on pivoting the brand toward niche indications (CKD, post-MI) and developing loyalty programs rather than acquisition-focused field efforts.